Get In Touch

Publications

G. Lodde, J. Dollani, W. Galetzka, P. Mohr, F. Meier, R. Gutzmer, M. Weichenthal, J. Utikal, R. Herbst, U. Leiter, C. Pfohler, B. Schilling, P. Terheyden, C. Berking, A. Sucker, A. Stang, F. Rambow, D. Tilkorn, A. Roesch, A. Zaremba, L. Zimmer, A. Tasdogan, D. Schadendorf, S. Ugurel, K. Griewank, and E. Livingstone.
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma. 

Br J Dermatol. 2026. [doi] [url]

M. Baures, A. S. Vieira Aleixo, E. Pacreau, A. Koshy, V. Friedrich, M. Diedisheim, M. Raigel, Y. Hua, C. Dariane, F. Boutillon, L. Kenner, J. C. Marine, G. Laverny, D. Metzger, F. Rambow, J. E. Guidotti, and V. Goffin.
Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy.

EMBO Mol Med. 2026. [doi] [url]

C. M. Thielmann, J. A. Seier, L. Schielke, L. J. Albrecht, L. Zimmer, E. Livingstone, A. Zaremba, G. Lodde, J. Dissemond, W. Sondermann, F. Krefting, A. Tasdogan, A. Roesch, E. Hadaschik, F. Rambow, K. Griewank, S. Ugurel, D. Schadendorf, and J. M. Placke. 
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients. 

Front Immunol. 2025. [doi] [url]

K. Theunis, S. Vanuytven, I. Claes, J. Geurts, F. Rambow, D. Brown, M. Van Der Haegen, O. Marin-Bejar, A. Rogiers, N. Van Raemdonck, E. Leucci, J. Demeulemeester, A. Sifrim, J. C. Marine, and T. Voet.
Single-cell genome and transcriptome sequencing without upfront whole-genome amplification reveals cell state plasticity of melanoma subclones. 

Nucleic Acids Res. 2025. [doi] [url]

Y. Hua, L. Weng, F. Zhao, and F. Rambow. 
SeuratExtend: streamlining single-cell RNA-seq analysis through an integrated and intuitive framework.

Gigascience. 2025. [doi] [url]

S. Dandou, J. A. Vendrell, J. Solassol, B. Louveau, C. Lebbe, S. Mourah, F. Rambow, E. Richard, S. Du Manoir, A. Mange, P. J. Coopman, O. Radulescu, and R. M. Larive. 
MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors. 

Sci Data. 2025. [doi] [url]

S. Egea-Rodriguez, R. Varaljai, T. M. Nordmann, R. Lubis, M. Philip, F. Rambow, A. Roesch, M. Flaig, S. Horn, R. Stoll, F. Zhao, A. Paschen, B. Klebl, I. D. Hickson, D. Schadendorf, M. Mann, and I. Helfrich. 
RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma. 

Clin Transl Med. 2025. [doi] [url]